Acadia Pharmaceuticals (ACAD) PT Raised to $42 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $20.76 --0%
Rating Summary:
16 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 38 | New: 6
Rating Summary:
16 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 38 | New: 6
Join SI Premium – FREE
Cantor Fitzgerald analyst Sarah James raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $42.00 (from $36.00) while maintaining a Overweight rating.
You May Also Be Interested In
- JPMorgan Downgrades Hanwha Solutions Corp (009830:KS) to Neutral
- Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
- Coal India Ltd (COAL:IN) PT Lowered to INR427 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
